NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD
NASDAQ:MOLN (2/21/2025, 8:00:01 PM)
4.681
-0.23 (-4.75%)
The current stock price of MOLN is 4.681 USD. In the past month the price decreased by -13.23%. In the past year, price increased by 16.73%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 162 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
MOLECULAR PARTNERS AG -ADR
Wagistrasse 14
Schlieren ZUERICH CH
CEO: Patrick Amstutz
Employees: 162
Company Website: https://www.molecularpartners.com/
Investor Relations: https://investors.molecularpartners.com/
Phone: 41447557700
The current stock price of MOLN is 4.681 USD. The price decreased by -4.75% in the last trading session.
The exchange symbol of MOLECULAR PARTNERS AG -ADR is MOLN and it is listed on the Nasdaq exchange.
MOLN stock is listed on the Nasdaq exchange.
9 analysts have analysed MOLN and the average price target is 12.04 USD. This implies a price increase of 157.12% is expected in the next year compared to the current price of 4.681. Check the MOLECULAR PARTNERS AG -ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MOLECULAR PARTNERS AG -ADR (MOLN) has a market capitalization of 172.56M USD. This makes MOLN a Micro Cap stock.
MOLECULAR PARTNERS AG -ADR (MOLN) currently has 162 employees.
MOLECULAR PARTNERS AG -ADR (MOLN) has a support level at 4.67 and a resistance level at 4.88. Check the full technical report for a detailed analysis of MOLN support and resistance levels.
The Revenue of MOLECULAR PARTNERS AG -ADR (MOLN) is expected to decline by -25% in the next year. Check the estimates tab for more information on the MOLN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MOLN does not pay a dividend.
MOLECULAR PARTNERS AG -ADR (MOLN) will report earnings on 2025-03-06, after the market close.
MOLECULAR PARTNERS AG -ADR (MOLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.07).
The outstanding short interest for MOLECULAR PARTNERS AG -ADR (MOLN) is 0.16% of its float. Check the ownership tab for more information on the MOLN short interest.
ChartMill assigns a technical rating of 1 / 10 to MOLN. When comparing the yearly performance of all stocks, MOLN turns out to be only a medium performer in the overall market: it outperformed 55.47% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to MOLN. The financial health of MOLN is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months MOLN reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 23.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.48% | ||
ROE | -44.4% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 82% to MOLN. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 17.79% and a revenue growth -25% for MOLN